Journal article
Coverage With Evidence Development Study Shows Benefits in Patients With Migraine Treated With Remote Electrical Neuromodulation
The American journal of managed care, v 31(11), pp e315-e321
01 Nov 2025
PMID: 40834199
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
OBJECTIVE: Migraine affects millions of individuals in the US, resulting in high health care costs and productivity loss. Traditional medications are often limited in effectiveness and tolerability, creating a need for accessible nonpharmacologic options. This coverage with evidence development (CED) study assessed the necessity of the remote electrical neuromodulation (REN) wearable device for migraine treatment as a standard payer-covered treatment. STUDY DESIGN: Real-world postmarketing CED study in 2 clinics for 14 months. METHODS: Members (aged 12-75 years) of a major US health insurer (Highmark Inc) diagnosed with migraine were prescribed REN as part of their clinical care. Effectiveness was evaluated by change in Migraine Disability Assessment (MIDAS) score from baseline to 3 months of treatment and by prospective pain and disability reports 2 hours post treatment. Utilization was measured through prescription fulfillment and safety via adverse event reports. RESULTS: A total of 381 patients (mean [SD] age, 40.5 [13.2] years; 91.1%female) participated. Change in MIDAS score was calculated from all participants who answered the questionnaire twice (n = 116), showing a significant and clinically meaningful mean (SD) improvement of-12.1 (51.8) points (P = .014), from 58.3 (59.0) to 46.2 (44.1). Of the participants, 77.8% reported pain relief and 33.3% reported pain freedom; 70.6% and 50.0% reported relief and freedom from functional disability, respectively. Patients used a mean (SD) of 4.0 (3.1) devices annually (extrapolated). Three minor adverse events were reported. These positive outcomes led to the inclusion of REN as a standard treatment for migraine under Highmark policy. CONCLUSIONS: REN leads to significant clinical and functional benefits in patients with migraine. Additional health insurers are encouraged to consider REN as a standard covered treatment.
Metrics
1 Record Views
Details
- Title
- Coverage With Evidence Development Study Shows Benefits in Patients With Migraine Treated With Remote Electrical Neuromodulation
- Creators
- Andrea Synowiec - Allegheny Hlth Network, Pittsburgh, PA USAAlit Stark-Inbar - Theranica Bio-Electronics Ltd. (Israel)Dolores Dominguez Santamaria - Allegheny Hlth Network, Pittsburgh, PA USAMatthew Fickie - Highmark Inc, Pittsburgh, PA USAStephen Ross - Pennsylvania State University
- Publication Details
- The American journal of managed care, v 31(11), pp e315-e321
- Publisher
- Managed Care & Healthcare Communications Llc
- Number of pages
- 7
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Neurology
- Web of Science ID
- WOS:001626815600001
- Scopus ID
- 2-s2.0-105022802812
- Other Identifier
- 991022193595404721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
Source: SDGs in the Output
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Health Care Sciences & Services
- Health Policy & Services